Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term ...

Q4 2024 Management View CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue increasing by 18% year-over-year and non-GAAP diluted EPS ...

Adjusted EPS of $0.92 topped estimates of $0.53. Revenue climbed to $747 million, beating the forecasted $712 million. Net ...

BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...

Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock following a Q4 Voxzogo ...

BioMarin Pharmaceutical Inc. ( NASDAQ: BMRN) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO ...

UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...

Total Revenues increased 16% year over year, driven by Voxzogo contributions from new patient starts in all regions. In the quarter, revenues from BioMarin's Enzyme Therapies increased 9% ...

Die Analysten von Oppenheimer haben am Montag ihre Einschätzung der BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Aktie von "Perform" auf "Outperform" angehoben und ein Kursziel von 98,00 US-Dollar fest ...

VOXZOGO for achondroplasia experienced 56% year-over-year growth, driven by global expansion and increased penetration in younger pediatric patients. Management also revealed plans to expand ...